4 results on '"Uleri, Alessandro"'
Search Results
2. Active surveillance for low-risk prostate cancer with high tumor burden at biopsy: lessons learned from a contemporary radical prostatectomy cohort.
- Author
-
Oliva, Jauffray, Anastay, Vassili, Baboudjian, Michael, Roumiguié, Mathieu, Peltier, Alexandre, Dariane, Charles, Fiard, Gaelle, Roumeguère, Thierry, Diamand, Romain, Bakhri, Mohamed, Beauval, Jean-Baptiste, Long-Depaquit, Thibaut, Ploussard, Guillaume, and Uleri, Alessandro
- Subjects
LOGISTIC regression analysis ,RADICAL prostatectomy ,WATCHFUL waiting ,STATISTICAL association ,PROSTATE cancer ,SENSITIVITY analysis - Abstract
Introduction: To investigate whether initial tumor burden at biopsy could predict adverse features after radical prostatectomy (RP) in International Society of Urological Pathology (ISUP) 1 prostate cancer (PCa) patients. Methods: This retrospective study was conducted in six referral centers. The cohort included patients with ISUP 1 PCa at systematic and MRI-targeted biopsy. We defined a high tumor burden at biopsy if ≥ 20% of cores were positive. The endpoint of the study was adverse features at RP, defined as ≥ pT3a stage and/or N1 and/or ISUP ≥ 3. Sensitivity analyses were performed to assess associations between different thresholds on biopsy (percentage of positive cores [PPC] ≥ 25%, ≥ 33%, ≥ 50%, bilateral positivity and positive cores > 3) and adverse features. As the number of targeted biopsies sampled may influence the number of positive cores, we used a virtual biopsy model in which all targeted biopsy results were interpreted as a single targeted biopsy. Results: A total of 312 contemporary patients were included. At final pathology, 99 patients (32%) had adverse features. In multivariate logistic regression analysis, there was no statistical association between PPC > 20% and adverse features (OR = 1.22; 95%CI:0.69–2.22, p = 0.5). In sensitivity analysis, tumor burden at biopsy was not associated with the risk of adverse features, regardless of the definition used (all p > 0.05). When we considered a unique virtual targeted biopsy, tumor burden remained not associated with adverse features (all p > 0.05). Conclusions: ISUP 1 PCa tumor burden at biopsy did not predict adverse features in this study, suggesting that it should not be used alone as an exclusion criterion when assessing eligibility for active surveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach.
- Author
-
Baboudjian, Michael, Breda, Alberto, Roumeguère, Thierry, Uleri, Alessandro, Roche, Jean-Baptiste, Touzani, Alae, Lacetera, Vito, Beauval, Jean-Baptiste, Diamand, Romain, Simone, Guiseppe, Windisch, Olivier, Benamran, Daniel, Fourcade, Alexandre, Fiard, Gaelle, Durand-Labrunie, Camille, Roumiguié, Mathieu, Sanguedolce, Francesco, Oderda, Marco, Barret, Eric, and Fromont, Gaëlle
- Subjects
PROSTATE cancer ,WATCHFUL waiting ,MACHINE learning ,DIGITAL rectal examination ,RADICAL prostatectomy ,PARALLEL algorithms ,GLEASON grading system ,DISEASE risk factors - Abstract
Purpose: To develop new selection criteria for active surveillance (AS) in intermediate-risk (IR) prostate cancer (PCa) patients. Methods: Retrospective study including patients from 14 referral centers who underwent pre-biopsy mpMRI, image-guided biopsies and radical prostatectomy. The cohort included biopsy-naive IR PCa patients who met the following inclusion criteria: Gleason Grade Group (GGG) 1–2, PSA < 20 ng/mL, and cT1-cT2 tumors. We relied on a recursive machine learning partitioning algorithm developed to predict adverse pathological features (i.e., ≥ pT3a and/or pN + and/or GGG ≥ 3). Results: A total of 594 patients with IR PCa were included, of whom 220 (37%) had adverse features. PI-RADS score (weight:0.726), PSA density (weight:0.158), and clinical T stage (weight:0.116) were selected as the most informative risk factors to classify patients according to their risk of adverse features, leading to the creation of five risk clusters. The adverse feature rates for cluster #1 (PI-RADS ≤ 3 and PSA density < 0.15), cluster #2 (PI-RADS 4 and PSA density < 0.15), cluster #3 (PI-RADS 1–4 and PSA density ≥ 0.15), cluster #4 (normal DRE and PI-RADS 5), and cluster #5 (abnormal DRE and PI-RADS 5) were 11.8, 27.9, 37.3, 42.7, and 65.1%, respectively. Compared with the current inclusion criteria, extending the AS criteria to clusters #1 + #2 or #1 + #2 + #3 would increase the number of eligible patients (+ 60 and + 253%, respectively) without increasing the risk of adverse pathological features. Conclusions: The newly developed model has the potential to expand the number of patients eligible for AS without compromising oncologic outcomes. Prospective validation is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
- Author
-
Baboudjian, Michael, Diamand, Romain, Uleri, Alessandro, Beauval, Jean-Baptiste, Touzani, Alae, Roche, Jean-Baptiste, Lacetera, Vito, Roumeguère, Thierry, Simone, Giuseppe, Benamran, Daniel, Fourcade, Alexandre, Gondran-Tellier, Bastien, Fiard, Gaelle, Peltier, Alexandre, and Ploussard, Guillaume
- Subjects
- *
OVERTREATMENT of cancer , *MAGNETIC resonance imaging , *RADICAL prostatectomy , *PROSTATE biopsy , *WATCHFUL waiting , *PROSTATE cancer - Abstract
In our multicenter European study involving 1020 patients with Gleason grade group ≥2 prostate cancer on magnetic resonance imaging–targeted biopsy, the rate of downgrading at radical prostatectomy specimen was 17.5%, but the overall risk of targeted biopsy–induced overtreatment was only ∼2.7%. Our findings indicate that targeted biopsy results are accurate and should be used for decision-making without fearing overtreatment caused by imaging guidance. Targeted biopsy of the index prostate cancer (PCa) lesion on multiparametric magnetic resonance imaging (MRI) is effective in reducing the risk of overdiagnosis of indolent PCa. However, it remains to be determined whether MRI-targeted biopsy can lead to a stage shift via overgrading of the index lesion by focusing only on the highest-grade component, and to a subsequent risk of overtreatment. Our aim was to assess whether overgrading on MRI-targeted biopsy may lead to overtreatment, using radical prostatectomy (RP) specimens as the reference standard. Patients with clinically localized PCa who had positive MRI findings (Prostate Imaging-Reporting and Data System [PI-RADS] score ≥3) and Gleason grade group (GG) ≥2 disease detected on MRI-targeted biopsy were retrospectively identified from a prospectively maintained database that records all RP procedures from eight referral centers. Biopsy grade was defined as the highest grade detected. Downgrading was defined as lower GG for the RP specimen than for MRI-targeted biopsy. Overtreatment was defined as downgrading to RP GG 1 for cases with GG ≥2 on biopsy, or to RP low-burden GG 2 for cases with GG ≥3 on biopsy. We included 1020 consecutive biopsy-naïve patients with GG ≥2 PCa on MRI-targeted biopsy in the study. Pathological analysis of RP specimens showed downgrading in 178 patients (17%). The transperineal biopsy route was significantly associated with a lower risk of downgrading (odds ratio 0.364, 95% confidence interval 0.142–0.814; p = 0.022). Among 555 patients with GG 2 on targeted biopsy, only 18 (3.2%) were downgraded to GG 1 on RP. Among 465 patients with GG ≥3 on targeted biopsy, three (0.6%) were downgraded to GG 1 and seven were downgraded to low-burden GG 2 on RP. The overall risk of overtreatment due to targeted biopsy was 2.7% (28/1020). Our multicenter study revealed no strong evidence that targeted biopsy results could lead to a high risk of overtreatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.